IONS Q1 2019 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$297M+105.8% YoY

Gross Profit

$296M99.6% margin

Operating Income

$122M40.9% margin

Net Income

$84M28.4% margin

EPS (Diluted)

$0.62

QoQ Revenue Growth

+54.7%

Cash Flow

Operating Cash Flow

$108M

Free Cash Flow

$103M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$1.4B

Stockholders' Equity

$1.2B

Cash & Equivalents

$376M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$297M	$144M	+105.8%
Gross Profit	$296M	$144M	+105.1%
Operating Income	$122M	-$3M	+3781.8%
Net Income	$84M	-$1M	+6046.7%

Revenue Segments

Research and Development Revenue Under Collaborative Agreements

$229M63%

Commercial

$68M19%

SPINRAZA Royalties

$60M16%

Product

$7M2%

Licensing and Other Royalties

$2M0%